Cilofexor
- Generic Name
- Cilofexor
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22Cl3N3O5
- CAS Number
- 1418274-28-8
- Unique Ingredient Identifier
- YUN2306954
- Background
Cilofexor is under investigation in clinical trial NCT02943447 (Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis).
Madrigal's Resmetirom Shows Promise in NASH Treatment Where Others Have Failed
• Madrigal Pharmaceuticals' resmetirom demonstrated significant efficacy in the Phase 3 MAESTRO-NASH trial, achieving both primary endpoints of NASH resolution and liver fibrosis improvement.
• The once-daily oral thyroid hormone receptor β-selective agonist showed NASH resolution in 26-30% of treated patients versus 10% on placebo, positioning it as a potential first-approved therapy for this growing health concern.
• Resmetirom's success stands in stark contrast to Gilead's selonsertib, which failed its Phase 3 STELLAR-4 trial, highlighting the difficulty in developing effective NASH treatments despite the condition's multi-billion dollar market potential.
NASH Pipeline Shows Promise with 80+ Emerging Therapies in Development
• Over 80 companies are actively developing treatments for Non-Alcoholic Steatohepatitis (NASH), with Inventiva Pharma and Cirius Therapeutics leading with Phase III candidates lanifibranor and MSDC-0602K respectively.
• Lanifibranor, a triple PPAR agonist with FDA Breakthrough Therapy designation, demonstrates significant anti-inflammatory and antifibrotic properties, while MSDC-0602K selectively modulates the mitochondrial pyruvate carrier to improve metabolic parameters.
• Novel therapeutic approaches include Terns Pharmaceuticals' THR-β agonist TERN-501 and HighTide Biopharma's HTD1801, both showing promising results in reducing liver fat and improving metabolic markers in Phase II trials.
Gilead Presents New Liver Disease Research at AASLD 2024
• Gilead Sciences is presenting over 40 abstracts at The Liver Meeting 2024, showcasing new data across various liver diseases.
• Data from the RESPONSE trial will highlight the efficacy and safety of seladelpar (Livdelzi) in patients with PBC and compensated cirrhosis.
• An interim analysis of the Phase 3 MYR301 study will evaluate the long-term efficacy of bulevirtide monotherapy in chronic HDV patients post-treatment.
• Safety and tolerability outcomes for velpatasvir/sofosbuvir (Epclusa) in pregnant individuals with chronic HCV will also be presented.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath